Apogee's Eczema Drug Shows Promising Results, Challenging Industry Leaders
TL;DR Summary
Apogee Therapeutics' promising eczema drug showed strong efficacy in Phase 2 trials, outperforming rivals like Sanofi's Dupixent, but its shares fell sharply after the announcement. The drug could potentially rival Sanofi's top revenue-generating treatments if further trials succeed, with plans for Phase 3 testing in 2026.
- How This Small Biotech Is Looking To Take On Sanofi's Cash Cow Investor's Business Daily
- Apogee reports first data on long-acting eczema drug STAT
- Apogee claims IL-13 antibody sets new eczema treatment standard in phase 2 study Fierce Biotech
- Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss Endpoints News
- Positive 16-Week Findings Identified for APG777 in Patients with Atopic Dermatitis HCPLive
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
89%
422 → 46 words
Want the full story? Read the original article
Read on Investor's Business Daily